Relationship of serum imatinib trough level and response in CML patients: Long term follow-up

被引：34

作者：

Awidi, Abdalla ^{[1
]}

Ayed, Ayed O. ^{[1
]}

Bsoul, Nazzal ^{[1
]}

Magablah, Ahmad ^{[1
]}

Mefleh, Razan ^{[1
]}

Dweiri, Mohammad ^{[2
]}

Ramahi, Mohammad ^{[2
]}

Arafat, Eyad ^{[2
]}

Bishtawi, Mohammad ^{[2
]}

Marie, Lena ^{[3
]}

机构：

[1] Univ Jordan, Dept Hematol, Amman 11191, Jordan

[2] Minist Hlth, Dept Hematol, Amman, Jordan

[3] King Hussein Canc Ctr, Dept Med Oncol, Amman, Jordan

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 12期

关键词：

Imatinib; Serum levels; Leukemia; CML; Molecular response; ROC analysis; CHRONIC MYELOID-LEUKEMIA; MOLECULAR RESPONSES; PHARMACOKINETICS; THERAPY; IMPACT; PLASMA;

D O I：

10.1016/j.leukres.2010.07.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

One hundred and three patients with Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia (CML) in chronic phase who were on oral imatinib were included in this study. The study aimed to assess the relationship between imatinib trough serum levels and clinical outcome (as determined by molecular response) in Jordanian CML patients who have been on imatinib therapy for at least 12 months. The mean trough imatinib serum level in the group with complete molecular response (CMR) was 2891 +/- 856 ng/ml, the group with major molecular response (MMR) was 2337 +/- 434 ng/ml, the group with complete cytogenetic response (CCyR) was 1817 +/- 563 ng/ml, and the group without CCyR was 1723 +/- 673 ng/ml. A receiver operating characteristic (ROC) curve was constructed after dividing patient sample into two groups, those with MMR or better and those without MMR, in order to estimate a threshold for imatinib level that correlates with a favorable response (the former group), and analysis yielded a value of 2158 ng/ml. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1573 / 1575

页数：3

共 11 条

[1] Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: Methods' comparison [J].

Awidi, Abdalla ;

Salem, Isam I. ;

Najib, Naji ;

Mefleh, Razan ;

Tarawneh, Bothainah .

LEUKEMIA RESEARCH, 2010, 34 (06) :714-717

[2] Therapeutic drug monitoring in CML patients on imatinib [J].

Blasdel, Carolyn ;

Egorin, Merrill J. ;

Lagattuta, Theodore F. ;

Druker, Brian J. ;

Deininger, Michael W. .

BLOOD, 2007, 110 (05) :1699-1701

[3] Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia [J].

Cortes, J. E. ;

Egorin, M. J. ;

Guilhot, F. ;

Molimard, M. ;

Mahon, F-X .

LEUKEMIA, 2009, 23 (09) :1537-1544

[4] Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy [J].

Hughes, Timothy P. ;

Branford, Susan ;

White, Deborah L. ;

Reynolds, John ;

Koelmeyer, Rachel ;

Seymour, John F. ;

Taylor, Kerry ;

Arthur, Chris ;

Schwarer, Anthony ;

Morton, James ;

Cooney, Julian ;

Leahy, Michael F. ;

Rowlings, Philip ;

Catalano, John ;

Hertzberg, Mark ;

Filshie, Robin ;

Mills, Anthony K. ;

Fay, Keith ;

Durrant, Simon ;

Januszewicz, Henry ;

Joske, David ;

Underhill, Craig ;

Dunkley, Scott ;

Lynch, Kevin ;

Grigg, Andrew .

BLOOD, 2008, 112 (10) :3965-3973

[5] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[6] Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study [J].

Larson, Richard A. ;

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Riviere, Gilles J. ;

Krahnke, Tillmann ;

Gathmann, Insa ;

Wang, Yanfeng .

BLOOD, 2008, 111 (08) :4022-4028

[7] Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example [J].

Li-Wan-Po, Alain ;

Farndon, Peter ;

Craddock, Charles ;

Griffiths, Michael .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (04) :369-374

[8] Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients [J].

Peng, B ;

Hayes, M ;

Resta, D ;

Racine-Poon, A ;

Druker, BJ ;

Talpaz, M ;

Sawyers, CL ;

Rosamilia, M ;

Ford, J ;

Lloyd, P ;

Capdeville, R .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :935-942

[9] Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia [J].

Picard, Stephane ;

Titier, Karine ;

Etienne, Gabriel ;

Teilhet, Ernmanuelle ;

Ducint, Dominique ;

Bernard, Marie-Agnes ;

Lassalle, Regis ;

Marit, Gerald ;

Reiffers, Josy ;

Begaud, Bernard ;

Moore, Nicholas ;

Molimard, Mathieu ;

Mahon, Francois-Xavier .

BLOOD, 2007, 109 (08) :3496-3499

[10] PLASMA OR SERUM IN THERAPEUTIC DRUG-MONITORING AND CLINICAL TOXICOLOGY [J].

UGES, DRA .

PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1988, 10 (05) :185-188

← 1 2 →